Advancing Treatments for Post-Traumatic Stress Disorder
Hybrid Public Meeting: In-Person and Virtual
September 6, 2024 | 1-3:30pm (eastern)
The Reagan-Udall Foundation for the FDA, in support of FDA’s ongoing focus on understanding medical need for PTSD treatment with the goal of facilitating treatment development, will convene “Advancing Treatments for Post-Traumatic Stress Disorder,” a public meeting with stakeholder comment.
This hybrid event, with both virtual and in-person attendance options, will feature a panel discussion with federal partners to explore efforts to accelerate treatment development for PTSD, including psychedelic drug development. Then we will open the mics for stakeholder comment, inviting people with lived PTSD experience, including veterans, family members, and patient advocates; researchers and scientists; and drug developers.
Thirty stakeholders will have up to three minutes each to present public comment either virtually or in-person. Note the deadline to request to present stakeholder comment is 12pm (eastern) on September 3. The Foundation will work to ensure a variety of representative voices can be heard. Speakers will be notified by September 4. If you prefer to submit written comments to the Foundation, please submit up to two pages of comments to PTSD@reaganudall.org. Comments will be accepted through September 20. Questions can also be submitted to this email address.
Use the appropriate button below to register. To express interest in speaking, please select the "With Request to Provide Public Comment" option listed on the registration page.
In-person venue address:
1333 New Hampshire Ave., NW, Washington, DC 20036
Funding Disclosure: This activity is one part of a multi-part Foundation project related to substance use disorder. The multi-part project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of an overall award of $1,720,109 of federal funds (100% of the project). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA, HHS, or the U.S. Government. For more information, please visit FDA.gov.